Drug Approval | June 01, 2022
FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Perrigo expects to launch Omeprazole Minis later this year
Manamed, a pioneering Medical Technology development company, has been granted FDA approval on its latest orthopaedic recovery device, ManaSport.
The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Subscribe To Our Newsletter & Stay Updated
